<DOC>
	<DOC>NCT00387153</DOC>
	<brief_summary>Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.</brief_summary>
	<brief_title>Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer</brief_title>
	<detailed_description>MPC-2130 Phase 1 Clinical study was designed to evaluate its safety and pharmacokinetic profile in patients with advanced metastatic tumors or blood cancers as well as refractory cancers that progressed despite previous chemotherapy.</detailed_description>
	<criteria>1. Be capable of understanding the informed consent form (ICF) and complying with the protocol, and must sign the ICF prior to the performance of any study related procedures; 2. Have cancer that is nonresponsive despite prior treatment with current standard of care regimens or for whom there are no available effective therapies; 3. Have measurable or evaluable neoplastic disease; 4. Be greater than or equal to age 18; 5. Have and ECOG Performance Status score of less than or equal to 2; 6. Have adequate organ function defined by: 1. Liver function tests (AST &amp; ALT) less than or equal to 3 times the upper limit of normal (ULN); 2. Bilirubin less than or equal to 1.5 X ULN; 3. Serum Creatinine less than or equal to 1.5 X ULN; 4. Hemoglobin greater than or equal to 8.0 g/dL; 7. Have recovered or stabilized from clinically significant toxicities of prior chemotherapy, surgery, or radiotherapy; 8. Have left ventricular ejection fraction (LVEF) of greater than or equal to 45% by multiple gated acquisition (MUGA) scan or echocardiogram. 1. Have had a prior serious, uncontrollable hypersensitivity reaction to Cremophor EL; 2. Be pregnant or lactating (women of childbearing potential must use appropriate birth control (abstinence, barrier methods, oral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records); 3. Receive any other anticancer treatment or investigational therapy within 14 days prior to day 1; or within 6 weeks after prior mitomycin C or nitrosourea. Patients with advanced prostate cancer may continue to receive leutinizing hormonereleasing hormone (LHRH) therapy while in this study; 4. Have previously enrolled in this trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Blood Cancers</keyword>
</DOC>